Page 19 - Read Online

Page 14 of 14 Lust et al. Vessel Plus 2021;5:7 I http://dx.doi.org/10.20517/2574-1209.2020.52

14. Bertrand-Thiebault C, Ferrari L, Boutherin-Falson O, et al. Cytochromes P450 are differently expressed in normal and varicose human
saphenous veins: linkage with varicosis. Clin Exp Pharmacol Physiol 2004;31:295-301.
15. Zhao H, Hiroi T, Hansen BS, Rade JJ. Cyclic stretch induces cyclooxygenase-2 gene expression in vascular endothelial cells via
activation of nuclear factor kappa-beta. Biochem Biophys Res Commun 2009;389:599-601.
16. Avendaño MS, Martínez-Revelles S, Aguado A, et al. Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension.
Br J Pharmacol 2016;173:1541-55.
17. Pfisterer L, Meyer R, Feldner A, Drews O, Hecker M, Korff T. Bortezomib protects from varicose-like venous remodeling. FASEB J
2014;28:3518-27.
18. Eschrich J, Meyer R, Kuk H, Wagner AH, Noppeney T, Debus S, et al. Varicose remodeling of veins is suppressed by 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors. J Am Heart Assoc 2016;5:e002405.
19. Kuk H, Arnold C, Meyer R, Hecker M, Korff T. Magnolol inhibits venous remodeling in mice. Sci Rep 2017;7:17820.
20. Kuk H, Arnold C, Wagner AH, Hecker M, Sticht C, Korff T. Glycyrrhetinic acid antagonizes pressure-induced venous remodeling in
mice. Front Physiol. 2018;9:320.
21. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2019;176:1038-50.
22. Kirkby NS, Lundberg MH, Harrington LS, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of
prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A 2012;109:17597-602.
23. Zhang J, Zou F, Tang J, et al. Cyclooxygenase-2-derived prostaglandin E 2 promotes injury-induced vascular neointimal hyperplasia
through the E-prostanoid 3 receptor. Circ Res 2013;113:104-14.
24. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase
type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-54.
25. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted
human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler
Thromb Vasc Biol 1999;19:646-55.
26. Kirkby NS, Chan MV, Zaiss AK, et al. Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-kappaB and NFAT
transcriptional pathways. Proc Natl Acad Sci U S A 2016;113:434-9.
27. Nakayama T. Genetic polymorphisms of prostacyclin synthase gene and cardiovascular disease. Int Angiol 2010;29(2 Suppl):33-42.
28. Midgett C, Stitham J, Martin K, Hwa J. Prostacyclin receptor regulation--from transcription to trafficking. Curr Mol Med 2011;11:517-28.
29. Yokoyama C, Yabuki T, Shimonishi M, et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and
renal infarction. Circulation 2002;106:2397-403.
30. Foudi N, Gomez I, Benyahia C, Longrois D, Norel X. Prostaglandin E2 receptor subtypes in human blood and vascular cells. Eur J
Pharmacol 2012;695:1-6.
31. Wang M, Ihida-Stansbury K, Kothapalli D, et al. Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.
Circulation 2011;123:631-9.
32. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical
selectivity into clinical read-outs. J Clin Invest 2001;108:7-13.
33. Raju S, Knight A, Lamanilao L, Pace N, Jones T. Peripheral venous hypertension in chronic venous disease. J Vasc Surg Venous Lymphat
Disord 2019;7:706-14.
34. Agus GB, de Angelis R, Mondani P, Moia R. Double-blind comparison of nimesulide and diclofenac in the treatment of superficial
thrombophlebitis with telethermographic assessment. Drugs 1993;46 Suppl 1:200-3.